CAELUS PHARMACEUTICALS Trademark
Trademark Overview
On Wednesday, June 5, 2024, a trademark application was filed for CAELUS PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the CAELUS PHARMACEUTICALS trademark a serial number of 79399417. The federal status of this trademark filing is NEW APPLICATION - ASSIGNED TO EXAMINER as of Monday, December 16, 2024. This trademark is owned by Caelus Pharmaceuticals B.V.. The CAELUS PHARMACEUTICALS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:
Scientific and technological services, and also assorted development and design; medical and pharmacological research services; development of pharmaceutical preparations, including vaccines and medicines; development of pharmaceutical products, carrying out evaluation of pharmaceutical products, conducting testing of pharmaceutical products, research in the field of pharmaceutical products, including medicines and vaccines; research in the field of pharmaceutical products, medicines and vaccines; laboratory research services related to pharmaceutical products, including medicines and vaccines; research and development in the field of new pharmaceutical products, including medicines and vaccines; research and development in the field of new products, food supplements and supplements, food for medical use; research and development in the field of new food supplements for human consumption; scientific research in the field of pharmacy; scientific research in the field of food and food su...
General Information
| Serial Number | 79399417 |
| Word Mark | CAELUS PHARMACEUTICALS |
| Filing Date | Wednesday, June 5, 2024 |
| Status | 638 - NEW APPLICATION - ASSIGNED TO EXAMINER |
| Status Date | Monday, December 16, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Scientific and technological services, and also assorted development and design; medical and pharmacological research services; development of pharmaceutical preparations, including vaccines and medicines; development of pharmaceutical products, carrying out evaluation of pharmaceutical products, conducting testing of pharmaceutical products, research in the field of pharmaceutical products, including medicines and vaccines; research in the field of pharmaceutical products, medicines and vaccines; laboratory research services related to pharmaceutical products, including medicines and vaccines; research and development in the field of new pharmaceutical products, including medicines and vaccines; research and development in the field of new products, food supplements and supplements, food for medical use; research and development in the field of new food supplements for human consumption; scientific research in the field of pharmacy; scientific research in the field of food and food supplements for the human body. |
Classification Information
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, July 8, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Caelus Pharmaceuticals B.V. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 98 - Unknown |
| Address | NL |
Trademark Events
| Event Date | Event Description |
| Friday, July 5, 2024 | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB |
| Monday, July 8, 2024 | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
| Friday, July 12, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, July 12, 2024 | APPLICATION FILING RECEIPT MAILED |
| Monday, December 16, 2024 | ASSIGNED TO EXAMINER |
